Posted on

Cbd oil for early onset dementia

A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC

* Corresponding Author: Tae Han Yook. Department of Acupuncture & Moxibustion Medicine, Korean Medicine Hospital of Woosuk University, 46, Eoeun-ro, Wansan-gu, Jeonju 54987, South Korea. Phone: +82-063-220-8622, E-mail: [email protected]

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

This study was to discuss the research trend of dementia treatment using cannabis for the purpose of providing the basis of cannabis use for medical purposes in the future.

Methods

This study searched publications, which were registered to databases or published by Aug 22, 2019, and targeted the full-text or abstracts of these publications. We selected the final nine studies met all selection criteria.

Results

These results implied that the CBD components of cannabis might be useful to treat and prevent AD because CBD components could suppress the main causal factors of AD. Moreover, it was suggested that using CBD and THC together could be more useful than using CBD or THC alone.

Conclusion

We hope that there will be a solid foundation to use cannabis for medical use by continuously evaluating the possibility of using cannabis for clinical purposes as a dementia treatment substance and cannabis can be used as a positive tool.

1. Introduction

The interest in senile disease is rising gradually because aging society has become a more common phenomenon. Types of dementia include AD, vascular dementia, paralytic dementia, Lewy body dementia, carbon monoxide induced dementia, and trauma dementia [1,2]. The onset of AD has continued to increase since 1995, while the prevalence of vascular dementia is gradually decreasing. Therefore, AD draws attention from researchers [3]. AD is a disease that is caused by the gradual degeneration and death of cerebral cortical cells. The main symptoms are memory loss, cognitive decline and behavioral disorders [4]. Histopathologically, overall encephalatrophy, senile plaques, and neurofibromatosis (NFT) are the common characteristics of AD [5]. Acquired cognitive deficits caused by AD have a significant impact on the social life and activity of the patients [6]. Moreover, active treatment of memory disorders greatly affects the prognosis of AD patients [3]. Consequently, many researchers acknowledge the need for a therapeutic drug to restore the memory and cognitive damages of AD patients, and various studies have been conducted.

There are three Cannabis species: C. sativa, C. indica, and C. ruderalis [7]. Cannabidiol (CBD), which is attracting attention as medical cannabis, belongs to cannabinoids [8]. Cacao, the main ingredients of chocolate, and the caryophyllene of black pepper also belong to cannabinoids [9].

Cannabis contains at least 113 kinds of cannabinoids. THC (Δ-tetrahydrocannabidiol), CBD, CBG (Cannabigerol), and CBN (Cannabinol) are well-known cannabinoids and many studies have been conducted on them. [10] using rats have shown that THC killed cancer cells and reduced tumor size. It has been reported that CBG expands blood vessels and protects the nervous system [11]. Since CBN is effective for inflammation, pain control, and insomnia, patches containing CBN ingredients are commercially available for human use [12]. Despite these advantageous effects, its use is currently restricted in South Korea according to the Narcotics Control Act (Law No. 15939) in order to prevent health hazards due to drug abuse. However, cannabis is legally used for medical or recreational purposes in several states of the US [13]. Although the medical efficacy and effects of cannabis have been actively studied, cannabis research is quite lacking in South Korea. Therefore, the objective of this study was to discuss the research trend of dementia treatment using cannabis for the purpose of providing the basis of cannabis use for medical purposes in the future.

2. Materials and Methods

2.1. Search Method

This study searched publications, which were registered to databases or published by Aug 22, 2019, and targeted the full-text or abstracts of these publications. Three researchers independently searched electronic journals in EMBASE and Pubmed. Literature was searched using the keywords of “P(patient)&I(intervention)”. The search terms P and I are presented in Table 1 . After conducting a literature search, the lists of literature were merged into one document.

Table 1

Molecular Targets in Rheumatoid Arthritis

List
P ‘Alzheimer’s Disease’, ‘Dementia, Senile’, ‘Senile Dementia’, ‘Dementia, Alzheimer Type’, ‘Alzheimer Type Dementia’, ‘Alzheimer-Type Dementia (ATD)’, ‘Alzheimer Type Dementia (ATD)’, ‘Dementia, Alzheimer-Type (ATD)’, ‘Alzheimer Type Senile Dementia’, ‘Primary Senile Degenerative Dementia’, ‘Dementia, Primary Senile Degenerative’, ‘Alzheimer Sclerosis’, ‘Sclerosis, Alzheimer’, ‘Alzheimer Syndrome’, ‘Alzheimer Dementia’, ‘Alzheimer Dementias’, ‘Dementia, Alzheimer’, ‘Dementias, Alzheimer’, ‘Senile Dementia, Alzheimer Type’, ‘Acute Confusional Senile Dementia’, ‘Senile Dementia, Acute Confusional’, ‘Dementia, Presenile’, ‘Presenile Dementia’, ‘Alzheimer Disease, Late Onset’, ‘Late Onset Alzheimer Disease’, ‘Alzheimer’s Disease, Focal Onset’, ‘Focal Onset Alzheimer’s Disease’, ‘Familial Alzheimer Disease (FAD)’, ‘Alzheimer Disease, Familial (FAD)’, ‘Alzheimer Diseases, Familial (FAD)’, ‘Familial Alzheimer Diseases (FAD)’, ‘Alzheimer Disease, Early Onset’, ‘Early Onset Alzheimer Disease’, ‘Presenile Alzheimer Dementia’
I ‘Cannabi’, ‘Hemp Plant’, ‘Hemp Plants’, ‘Plant, Hemp’, ‘Plants, Hemp’, ‘Cannabis indica’, ‘Cannabis indicas’, ‘indicas, Cannabis’, ‘Marihuana’, ‘Marihuanas’, ‘Marijuana’, ‘Marijuanas’, ‘Ganja’, ‘Ganjas’, ‘Hashish’, ‘Hashishs’, ‘Hemp’, ‘Hemps’, ‘Bhang’, ‘Bhangs’, ‘Cannabis sativa’, ‘Cannabis sativas’, ‘sativas, Cannabis’

2.2. Selection criteria and outcome assessment

This study selected published studies using Cannabis sativa and its components for patients with dementia. The three researchers independently selected and excluded publications. When there was a discrepancy among them, all researchers discussed whether to include or exclude the publication. The extracted literature was analyzed first by in vivo and in vitro methods, and then by cannabis components used, and by subjects used to determine therapeutic effects.

3. Results

3.1. Description of the included studies

A total of 1,149 studies were searched through P & I cross-search, and 86 studies were identified after excluding duplicated studies. We first excluded studies that were not related with dementia or did not use Cannabis sativa and its components using the titles and abstracts of these publications and 21 were selected after the first screening. Afterward, we examined the contents of these 21 studies, five studies failed to obtain full text, five could not determine the efficacy of cannabis on dementia, and two were related to policy. Finally the final nine studies met all selection criteria [14–22] were selected ( Fig. 1 ).

Flowchart of trial selection process

3.2. In vitro studies using CBD for AD

Four out of five in vitro studies using CBD were performed on PC12 neuronal cells. The results showed that CBD activated the Peroxisome Proliferator-Activated Receptor-γ(P-PARγ) through the Wnt/β-catenin pathway. As a result, it protected PC12 cells from Aβ neurotoxicity and oxidation stress, increased cell survival, reduced ROS production, reduced lipid peroxidation, inhibited the hyperphosphirylation of tau protein, and inhibited AChE [14–17]. A study conducted on SH-SY5YAPP+ cells showed that it reduced Aβ production and actually decreased the APP full length protein levels. Additionally, CBD affected the selective activation of PPARγ [18].

3.3. In vivo studies using CBD for AD

Two in-vitro studies using CBD treated the right dorsal hippocampus of mice with human Aβ (1–42) peptide and applied CBD to evaluate the effects of CBD on neurotoxicity and inflammation. The results showed that CBD significantly inhibited the expression of GFAP, mRNA, and protein and reduced the expression of iNOS and IL-1β protein.19) Moreover, the effects of CBD were confirmed with and without the antagonist of PPARγ [20]. It was found that the blocking of PPARγ mitigated the effects of CBD on neural damage and CBD stimulated the neurogenesis of the hippocampus through interactions [20].

3.4. In vivo studies using CBD-THC for AD

Two in-vivo studies using CBD and THC at the same time showed that the CBD+THC treatment was effective on the memory of AβPP/PS1 transgenic mice and the CBD+THC was more effective than CBD alone or THC alone treatments [21]. Moreover, the CBD+THC treatment reduced the GluR2/3 of aged AβPP/PS1 mice and increased the level of GABA-A Rα1 [22].

4. Discussion

The number of patients with dementia has been increasing gradually and it is predicted that it will reach 81.1 million in 2040 [23]. It is also forecasted that the number of patients with dementia will be 800,000 in South Korea in 2020 [24]. Additionally, the Ministry of Health and Welfare estimates that about 10% of the population aged 65 or older will suffer from dementia in 2025 and it will cost 30 trillion KRW to treat them [25]. However, we yet do not have a solid treatment to cure dementia and the current standard medications mainly focus only on delaying dementia and recovering symptoms [26].

Therefore, we conducted this study to provide a basis for the treatment of dementia using cannabis, which is currently illegal in South Korea but known to be effective against neuroinflammation, while an effective method is needed for treating dementia, which is gradually becoming a social problem.

This study conducted P&I cross-search targeting publications published or registered to databases by Aug 22, 2019, using the full-text and abstracts of publications. Finally, nine studies [14–22] were selected and analyzed.

The results of these studies confirmed that CBD activated the peroxisome proliferator-activated receptor-γ(PPARγ) through the Wnt/β-catenin pathway to protect PC12 cells from Aβ neurotoxicity and oxidation stress, increase cell survival, reduce ROS production, reduce lipid peroxidation, inhibit the hyperphosphirylation of tau protein, inhibit AChE, and stimulate the neurogenesis of the hippocampus.

Additionally, CBD+THC treatment to AβPP/PS1 transgenic mice revealed that CBD+THC treatment was effective in memory and CBD+THC treatment was more effective than CBD alone or THC alone treatment. These results implied that the CBD components of cannabis might be useful to treat and prevent AD because CBD components could suppress the main causal factors of AD. Moreover, it was suggested that using CBD and THC together could be more useful than using CBD or THC alone.

We hope that there will be a solid foundation to use cannabis for medical use by continuously evaluating the possibility of using cannabis for clinical purposes as a dementia treatment substance and cannabis can be used as a positive tool. ​ tool.

Table 2

Summary of the effects of CBD and CBD-THC combinations on AD

No. Study ID Model Effect
IN VITRO STUDIES USING CBD
1 Iuvone 2004 PC12 Neuronal Cells Protected against Aβ neurotoxicity and oxidative stress, increased cell survival and decreased ROS production and lipid peroxidation
2 Esposito 2006 PC12 Neuronal Cells Inhibited tau hyperphosphorylation
3 Eubanks 2006 PC12 Neuronal Cells Prevented transcription of pro-inflammatory genes
4 Alexandre 2017 PC12 Neuronal Cells Aβ-induced tau protein hyperphosphorylation is inhibited
5 Scuderi 2014 SH-SY5YAPP+ Cells Induced APP ubiquination and subsequently Aβ production and increased cell survival by reducing apoptotic rate
IN VIVO STUDIES USING CBD
6 Esposito 2007 Mice inoculated with human Aβ42 peptide Attenuated Aβ induced neuroinflammatory responses by decreasing expression of proinflammatory gene and mediators
7 Giuseppe 2011 Mice inoculated with human Aβ42 peptide Reduced reactive gliosis
IN VIVO STUDIES USING CBD-THC
8 Ester 2015 Young APPxPS1 transgenic mice (mixed background) Improved memory deficits in the two-object recognition task and the active avoidance task. Decreased soluble Aβ42 levels and changed plaque composition and reduced a strogliosis, microgliosis and inflammatory related molecules
9 Ester 2016 Aged APPxPS1 transgenic mice (mixed background) APP/PS1 mice are associated with reduced GluR2/3 and increased levels of GABA-A Rα1 in cannabinoid-treated animals

Acknowledgement

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. NRF-2018R1D1A1B07044595).

Footnotes

This paper meets the requirements of KS X ISO 9706, ISO 9706-1994 and ANSI/NISO Z39.48-1992 (Permanence of Paper).

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

1. Kim GN, Bae HS, Hwang EW, Jo SH. Study on the Application of Oriental Medical Evaluation to Dementia. JPPKM. 2014; 25 (4):383–8. doi: 10.7231/jon.2014.25.4.383. [CrossRef] [Google Scholar]

2. Park MS, Kim YM. Study on Syndrome Differentiation of Dementia. JPPKM. 2014; 28 (3):251–62. doi: 10.15188/kjopp.2014.06.28.3.251. [CrossRef] [Google Scholar]

3. Han DY, Park NE, Kim SH, Jeong DG. The Effect of Oral Administration of Herbal Medicines on Memory in Alzheimer’s Disease Animal Models: A Review of Animal Study Reports Published in Korea. JPPKM. 2017; 28 (4):359–71. [Google Scholar]

4. Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science. 2006; 314 (5800):777–81. doi: 10.1126/science.1132814. [PubMed] [CrossRef] [Google Scholar]

5. Oide T, Kinoshita T, Arima K. Regression stage senile plaques in the natural course of alzheimer’s disease. Neuropathology and Applied Neurobiology. 2006; 32 (5):539–56. doi: 10.1111/j.1365-2990.2006.00767.x. [PubMed] [CrossRef] [Google Scholar]

6. Qaseem A, Snow V, Cross J, Forciea M, Hopkins R, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008; 148 (5):370–8. doi: 10.7326/0003-4819-148-5-200803040-00008. [PubMed] [CrossRef] [Google Scholar]

7. Patricia R, Joseph S. Medical Marijuana and pain management. Peer-reviewed excellence in life care planning. 2019; 19 (3):20–5. doi: 10.1016/j.disamonth.2016.05.014. [CrossRef] [Google Scholar]

8. Ha SY. Perception Survey of the Use of Medical Marihuana Targeting Cancer-Patients and each of their Protectors. Korea: Hansung Univ; 2018. [in dissertation] [Google Scholar]

10. Takeda S, Ikeda E, Su S, Harada M, Okazaki H, Yoshioka Y, et al. Delta(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: Possible involvement of induced levels of PPAR alpha in MDA-MB-231 breast cancer cells. Toxicology. 2014; 326 (4):18–24. doi: 10.1016/j.tox.2014.09.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology. 2012; 219 (3):15. doi: 10.1007/s00213-011-2415-0. [PubMed] [CrossRef] [Google Scholar]

13. Vidot DC, Prado G, Hlaing WM, Arheart KL, Messiah SE. Emerging issues for our nation’s health: the intersection of marijuana use and cardiometabolic disease risk. J Addict Dis. 2014; 33 (1):1–8. doi: 10.1080/10550887.2014.882718. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J Neurochem. 2004; 89 (1):134–41. doi: 10.1111/j.1471-4159.2003.02327.x. [PubMed] [CrossRef] [Google Scholar]

15. Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med. 2006; 84 (3):253–8. doi: 10.1007/s00109-005-0025-1. [PubMed] [CrossRef] [Google Scholar]

16. Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, et al. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm. 2006; 3 (6):773–7. doi: 10.1021/mp060066m. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Vallée Alexandre, Lecarpentier Yves, Guillevin Rémy, Vallée Jean-Noël. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer’s disease. Acta Biochim Biophys Sin. 2017; 49 (10):853–66. doi: 10.1093/abbs/gmx073. [PubMed] [CrossRef] [Google Scholar]

18. Scuderi C, Steardo L, Esposito G. Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5Y APP+ Cells Through PPARγ Involvement. Phytother Res. 2014; 28 (7):1007–13. doi: 10.1002/ptr.5095. [PubMed] [CrossRef] [Google Scholar]

19. Esposito G, Scuderi C, Savani C, Steardo L, De Filippis D, Cottone P, et al. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. British Journal of Pharmacology. 2007; 151 (8):1272–9. doi: 10.1038/sj.bjp.0707337. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Giuseppe E, Caterina S, Marta V, Giuseppina IT, Valentina L, Daniele DF, et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLOS ONE. 2011; 6 (12):28668. doi: 10.1371/journal.pone.0028668. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Aso Ester, Alexandre SP, Esteban VL, Rafael M, Isidro F. Cannabis-Based Medicine Reduces Multiple Pathological Processes in AβPP/PS1 Mice. J Alzheimers Dis. 2015; 43 (3):977–92. doi: 10.3233/JAD-141014. [PubMed] [CrossRef] [Google Scholar]

22. Aso Ester, Andrés-B Pol, Isidro F. Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model. J Alzheimers Dis. 2016; 54 (3):903–12. doi: 10.3233/JAD-160533. [PubMed] [CrossRef] [Google Scholar]

23. Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366 (9503):2112–7. doi: 10.1016/S0140-6736(05)67889-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Seoul National University Hospital. Nationwide study on the prevalence of dementia in Korea elders. Seoul: Ministry for Health, Welfare and Family affairs; 2008. [Google Scholar]

25. Ministry of Health and Welfare. The 3rd comprehensive plan for dementia management (‘16 ~ ‘20) Seoul: Ministry of Health and Welfare; 2015. [Google Scholar]

26. Cho HG, Kang HJ, Go YJ, Park JW, Park SG, Jeong PS, et al. Tendency of Korean Herbal Medicine Prescriptions Used for Dementiain Korean Experimental Researches Mainly about Domestic Dissertations for a Degree. JKMR. 2014; 24 (4):29–40. [Google Scholar]

Articles from Journal of Pharmacopuncture are provided here courtesy of Korean Pharmacopuncture Institute

CBD Oil for Alzheimer’s & Dementia: How to Use & Dosage

Hemp and CBD oil were federally legalized with the 2018 Farm Bill, but scientists have been researching cannabidiol and its potential benefits for many years prior to the cannabis boom.

CBD products are gaining popularity at a rapid pace, mainly due to the number of conditions potentially alleviated by this compound.

Researchers are discovering new symptoms that CBD may be able to treat or help with in some way — from anxiety to inflammation and neurodegenerative diseases like dementia. CBD may provide relief to thousands of people across the country.

In this article, I’ll dive specifically into the potential application of CBD for dementia and the collateral damage it does to individuals suffering from this disease.

I want to explain the ins and outs of using CBD oil, how it can interact with dementia, and guide you through the brands that currently offer the best CBD products on the market.

Best CBD Oils for Dementia

Not all CBD is made equal. In fact, there’s a large degree of difference when it comes to the quality of ingredients in different CBD oils.

If you’re using this supplement for dementia, it’s important to find something clean and as high quality as possible — preferably in a higher potency.

Here are my top 3 recommended products that meet those requirements:

1. Royal CBD

Get 15% off all Royal CBD products. Use code “CFAH” at checkout.

  • Royal CBD uses organic hemp from local farmers
  • The company makes its products with supercritical CO2 extraction
  • Available as full-spectrum CBD and isolate
  • Four potency strengths to choose from: 250mg, 500mg, 1000mg, and 2500mg
  • The oil is potent — it contains up to 83.3 mg of CBD in each mL
  • Suspended in premium MCT oil for better taste and improved absorption
  • Every batch of product has been tested for potency and purity in a 3rd-party laboratory
  • The 2500 mg oil is available only in the unflavored option
  • Royal CBD products are slightly more expensive than the competition given the quality of ingredients this company uses
My Thoughts on Royal CBD:

Royal CBD is a rising star of premium CBD oils — offering high-quality products made from organically-grown American hemp. The oil contains the full spectrum of cannabinoids and terpenes, providing the synergy from these compounds and contributing to the higher efficacy of CBD.

Aside from extracting its oil with pressurized CO2, Royal CBD sends each batch of product to independent laboratories for testing. This is used to confirm the potency and purity of every bottle sold.

The oil offers 250 mg to 2500 mg of full-spectrum CBD per bottle, suiting both novice consumers and experienced users or those with more severe symptoms.

I like how this product tastes. Because it’s suspended in high-quality MCT oil, it doesn’t leave that bitter, earthy aftertaste on the tongue. The flavor is masked by nutty rather than earthy notes.

But if you prefer other forms of administration, Royal CBD offers convenient soft gel capsules (25 mg of CBD per piece) and isolate-based gummies (10 mg of CBD per count). These forms may not have the fastest onset but are easier to dose and take on the go.

2. CBDPure

  • CBDPure’s products are sourced from organic hemp grown in Colorado
  • The company uses CO2 extraction in all their products
  • The oil is sold in larger bottles than the competition (60 mL)
  • These products are made with full-spectrum hemp extract
  • The entire product lineup has been tested in an independent laboratory for quality assurance
  • Narrow product range
  • The oil is less potent than Royal CBD
  • No isolates available
My Thoughts on CBDPure:

If you don’t know where to start and need plenty of information about each stage of the CBD oil manufacturing stage, CBDPure is one of the best brands you can choose. This company is very transparent and uses organic hemp in every product they offer.

Similar to Royal CBD, CBDPure prefers to keep things simple, offering two types of products — oil drops and capsules.

Their CBD oil comes in 60 mL bottles but is slightly less potent than Royal CBD, so you may choose this option if you benefit from lower doses, which isn’t common for people with dementia symptoms.

If you want a product that will give you more CBD and offer consistent dosing, you may go for CBDPure softgels. Each capsule comes with 25 mg of full-spectrum cannabidiol.

3. CBDistillery

  • CBDistillery uses Colorado-grown hemp
  • The company’s products are available as ‘full-spectrum’ or ‘pure oil’ (zero THC)
  • Broad product selection
  • The oil is very potent — up to 5,000 mg of CBD per bottle
  • CBDistillery sends samples of their CBD oil to a third-party laboratory for thorough content analysis
  • It’s one of the most affordable brands on the market
  • Their hemp isn’t organic
  • The CBD oil is available only in the unflavored version
My Thoughts on CBDistillery:

CBDistillery is a Colorado-based brand with a diverse product selection. Out of all their products, my favorite is their full-spectrum CBD oil. Interestingly, this product is also available as pure oil, with no THC inside.

The oil comes in a wide potency range, from 250 to 5,000 mg of total CBD. The company caters to different types of CBD consumers and budgets.

Their oil may not be as high quality as Royal CBD or CBDPure — it’s not made from organic hemp — but this is well justified by the cost of their products. CBDistillery doesn’t sell the best CBD oil out there, but that’s definitely the best CBD oil in this price range.

On top of making affordable CBD products, CBDistillery is known for its influence on raising awareness about the health benefits of cannabis. They have created the #CBDMOVEMENT hashtag to provide education for customers in their social media.

What is Dementia?

Dementia is not a disease, per se. Instead, it’s a group of conditions that impair the functioning of your brain.

Generally, dementia is characterized by the deterioration of at least two important brain functions, such as weakened judgment and memory loss. As a matter of fact, any form of dementia can compromise cognitive functioning.

As with every health condition, there are certain symptoms that can help diagnose dementia, namely:

  • Impairment of motor functions and coordination
  • Memory loss usually noticed first by a close family member
  • Personality changes
  • Difficulty with problem-solving or reasoning
  • Anxiety, agitation, depression, or paranoia
  • Confusion
  • Hallucinations and awkward behavior
  • Problems handling complex tasks

Is Dementia the Same as Alzheimer’s Disease?

Alzheimer’s is the most common form of dementia, so dementia is just a category that Alzheimer’s Disease belongs to. Yet, there are other forms of dementia besides Alzheimer’s.

Dementia can be categorized into four different forms of dementia:

  1. Frontotemporal dementia: the type where the nerve cells in the temporal and frontal lobes of the brain degenerate. Frontotemporal dementia affects the parts of the brain that control behavior, language, and personality
  2. Lewy Body Dementia: the most common type of progressive dementia, Lewy Body Dementia occurs when abnormal clumps of protein start to form in the brain.
  3. Vascular Dementia: it’s the second most prevalent form of dementia. It’s caused by the damage in the blood vessels that limits direct blood supply to the brain and may lead to blood vessel clogs or stroke.
  4. Mixed dementia: it typically involves some combination of Alzheimer’s Disease and other forms of dementia. While Alzheimer’s may strike those over the age of 65, mixed dementia occurs upon further progression.

What Are the Benefits of CBD for Dementia?

CBD has been proposed by scientists as a natural alternative for many serious conditions including memory loss conditions, anxieties, and sleep disorders.

CBD is a potent antioxidant, anti-inflammatory, and neuroprotectant, so it may greatly improve brain functioning, which is essential in slowing and halting the progression of neurodegenerative diseases.

Below I explain how CBD oil could improve different forms of dementia based on the latest scientific findings.

1. Alzheimer’s Disease

Research shows a clear link between CBD and the reduction of inflammation and brain cell decline.

Inflammation increases the negative impact of Alzheimer’s disease. It’s a core cause of this condition. The more inflamed the brain, the greater the damage.

Alzheimer’s sufferers often show a path of rapid decline and degeneration of brain cells in certain regions. Scientists have recently found that CBD has the potential of improving the plasticity of the hippocampal region — the part of the brain responsible for cognitive functioning and forming memories.

In clinical trials, researchers have found that the endocannabinoid system is involved in neurotransmission, neuropathology, and neurobiology of different forms of dementia, including Alzheimer’s Disease.

2. Vascular Dementia

As mentioned, people who have vascular dementia typically encounter problems with planning, reasoning, memory, judgment, and other thought processes due to brain damage from reduced blood flow to their brains.

A 2016 study conducted by the National Institute of Health (NIH) found that activating cannabinoid receptors in the brain promoted the recovery of blood flow to the brain.

3. Parkinson’s Disease Dementia

Parkinson’s is a progressive neurodegenerative disease mainly affecting middle-aged and elderly people. Some symptoms of dementia may be the result of Parkinson’s disease — referred to as Parkinson’s disease dementia.

Scientists suggest that Parkinson’s disease may derive from lowered dopamine production and is most commonly expressed by muscular strains, tremors, and slow, flawed movement.

A digestive imbalance may also be a significant factor in the progression of Parkinson’s and the seriousness of its symptoms. Cannabinoids such as CBD have been shown to produce neuroprotective and antioxidant effects on the brain which, along with its anti-inflammatory properties, can be effective in managing Parkinson’s disease-induced dementia.

4. Lewy Bodies Dementia

Lewy Bodies is a scientific name for the alpha-synuclein protein deposits in the brain. These buildups can lead to problems with judgment, sleeping, behavior, movement, and mood.

Research has found that CBD may reduce anxiety and stabilize mood. In addition, the anti-inflammatory effects of CBD can reduce the severity of motor symptoms and help with sleep regulation.

5. Frontotemporal Dementia

As the brain loses more cells in its frontal or temporal lobes, this can trigger symptoms of depression and psychosis. Unlike many antipsychotic drugs, CBD may alleviate tremors, anxiety, and rigidity without the side effects associated with prescription drugs.

6. Huntington’s Disease Dementia

Also known as Huntington’s chorea, this disease is an inherited disorder that leads to degeneration of brain cells — which often results in symptoms of dementia.

The earliest symptoms of this condition are often mild and involve problems with mood and concentration. As the disease progresses, a person may suffer from a general lack of coordination and an unsteady gait (walking motion).

A 2016 study conducted by researchers from the University of Madrid discovered that CBD’s antioxidant and anti-inflammatory properties can be beneficial for managing Huntington’s disease and is safe even at very high doses.

What Experts Say About CBD Oil and Dementia

Scientists are going to use a CBD/THC oral spray Sativex to treat dementia patients in the first major trial in the UK. The study is led by researchers at King’s College London and funded by Alzheimer’s Research UK.

Researchers will be investigating the efficacy of Sativex, a drug already approved for patients with multiple sclerosis, by observing 60 patients between the age of 55–90 who are living in care homes for the duration of the trial. The study will aim at easing aggression and agitation, one of the main symptoms of dementia.

Dag Aarsland, a psychiatrist and the professor supervising the trial says:

“Most often, people associate Alzheimer’s disease with memory problems, but this is just one aspect of a complex condition that can affect people in different ways. Many people with Alzheimer’s can become agitated or aggressive, and this can pose difficulties for the person with the condition and those closest to them.”

If full-spectrum extracts prove effective as a dementia treatment, this can be a breakthrough for modern medicine considering that scientists have been struggling to come up with effective solutions for almost two decades.

“With no new dementia treatments in over 15 years, it is vital that we test a wide range of approaches to find effective ways to help people living with the condition,” said David Reynolds, Ph.D., of Alzheimer’s Research U.K. Reynolds underlines the importance of finding a medicine that will not only slow or stop the progression of dementia but also benefits people’s day-to-day performance.

“Based on some preliminary studies in other populations, like younger individuals with bipolar disorder and schizophrenia, as well as animal studies, there is at least some reason to theorize these drugs would have a benefit,” follows Dr. Nathan Herrmann, head of geriatric psychiatry department at Sunnybrook Health Sciences Centre in Canada, showing support for his colleagues in the UK.

Sativex has equal amounts of THC and CBD. Hemp-derived CBD oil contains only 0.3% THC and there are no trials that would look into the effects of this cannabis solution on dementia.

What’s the Best CBD Oil Dosage for Dementia?

There are no definite dosage guidelines when it comes to using CBD oil for dementia. However, various studies have been performed on the efficacy of different CBD doses for Alzheimer’s patients.

A study conducted in 2014 found that higher concentrations of CBD may be required until the effects take hold. The study was conducted on transgenic mice.

Given the lack of regulation in the CBD marketplace, the best thing you can do is observe the effects of different dosages and report to a foundation or science institute that specializes in seeking new forms of dementia treatment. With more self-reports from patients, healthcare professionals will be able to come up with some general guidelines for people with dementia in the future.

Where to Buy CBD Oil for Dementia

If you’ve been considering taking hemp-derived CBD oil for dementia, you can buy one in a local cannabis dispensary or search for CBD products online.

I prefer buying CBD oil online. The majority of CBD supplements are sold this way, so you get access to a wider range of products. Cannabis dispensaries have plenty of CBD supplements as well, but they may not carry the best products out there, not to mention that they might have stood on the shelves for a long time after arrival — which is not the best way to store CBD oil.

Buying CBD oil online is also more convenient. You can easily check the reputation of your potential supplier. Always make sure that your manufacturer uses organic hemp, makes its products with CO2 extraction, and posts testing results from 3rd-party laboratory screening.

Finally, online stores are less expensive than dispensaries. Usually, you will pay around twice as much for CBD oil in a local dispensary than you would for a product ordered online.

It’s worth waiting the extra 2-3 days to get exactly what you’ve been looking for without spending an arm and a leg.

Final Thoughts on Using CBD Oil for Dementia

Dementia is a severe neurodegenerative condition. It’s not a disease per se; instead, it’s a set of symptoms that describe a predictable set of symptoms. It can take many forms, from Alzheimer’s Disease to vascular dementia and Lewy Bodies Dementia. Dementia can also result from the progress of other neurodegenerative diseases, such as Parkinson’s or Huntington’s Disease.

Scientists have been investigating the neuroprotectant properties of CBD and its influence on neurodegeneration for quite some time now. While the evidence isn’t conclusive yet, results from animal studies and preclinical trials indicate that the endocannabinoid system and cannabinoids can be used to prevent neurodegeneration and reverse its impact with consistent administration.

If you’re interested in trying CBD oil for dementia, make sure to contact your doctor first to figure out whether CBD is good for you, especially if you’re already using some medication.

  1. Prenderville, J. A., Kelly, Á. M., & Downer, E. J. (2015). The Role of Cannabinoids in Adult Neurogenesis. British Journal of Pharmacology, 172(16), 3950–3963.
  2. Walther, S., & Halpern, M. (2010). Cannabinoids and Dementia: A Review of Clinical and Preclinical Data. Pharmaceuticals (Basel, Switzerland), 3(8), 2689–2708.
  3. Karl, T., Cheng, D., Garner, B., Arnold, J.C. (2012). The Therapeutic Potential of the Endocannabinoid System for Alzheimer’s Disease. Expert Opinion on Therapeutic Targets, 16(4), 407–420.
  4. Benyo, Z., Ruisanchez, E., Leszl-Ishiguro, M., Sandor, P., Pacher, P. (2016). Endocannabinoids in Cerebrovascular Regulation. American Journal of Physiology. Heart and Circulatory Physiology, 310(7), 785–801.
  5. Peres, F. F., Lima, A. C., Hallak, J., Crippa, J. A., Silva, R. H., & Abílio, V. C. (2018). Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?. Frontiers in pharmacology, 9, 482.
  6. Ibeas Bih, C., Chen, T., Nunn, A. V., Bazelot, M., Dallas, M., & Whalley, B. J. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 12(4), 699–730.
  7. Maroon, J., & Bost, J. (2018). Review of the Neurological Benefits of Phytocannabinoids. Surgical Neurology International, 9, 91.
  8. Lopez-Sendon Moreno, J.L. et al. (2016). A Double-Blind, Randomized, Cross-Over, Placebo-Controlled, Pilot Trial With Sativex in Huntington’s Disease. Journal of Neurology, 263(7), 1390–1400.
  9. Cheng, D., Spiro, A.S., Jenner, A.M., Garner, B., Karl, T. (2014). Long-term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer’s Disease Transgenic Mice. Journal of Alzheimer’s Disease, 42(4), 1383–1396.
Nina Julia

Nina created CFAH.org following the birth of her second child. She was a science and math teacher for 6 years prior to becoming a parent — teaching in schools in White Plains, New York and later in Paterson, New Jersey.

Leave a comment Cancel reply

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Can CBD Help Seniors with Alzheimer’s & Dementia?

CBD, or cannabi diol , has been suggested as a treatment to help seniors with dementia manage their symptoms. While there is currently no evidence to show that CBD can stop, reverse, or prevent dementia , there is research that sho ws that it could help manage symptoms. This could be great news for families and seniors who are struggling with the effects of dementia. In this post, we will explore what CBD is along with how CBD can be used to help seniors deal with Alzheimer’s or related dementias.

What Is CBD?

Let’s start with the basics of CBD. It comes from the hemp plant , which is related to the marijuana plant . The plant is dried and the resin is extracted. This compound contains 2 parts: tetrahydrocannabinol (THC) and cannabidiol (CBD).

  • THC is the recreational form of cannabis, which is associated with generating a “high.” In the US, products with more than 0.2% THC are considered illegal.
  • CBD is the medicinal form of cannabis that generally helps improve mood and reduce damage caused by inflammation. It does not CBD is legal in various forms in 47 US states. It also does not exhibit the potential for dependence or health-related problems.

This distinction is important because CBD does not have the intoxicating feeling associated with THC. Instead, it has been shown t o have anti-anxiety properties that can help manage behavior and promote calm. Additionally, CBD is the main ingredient in recent FDA-approved medication, Epidiolex, to treat epilepsy.

CBD can be administered in different forms, but the most common is as oil, which can be dropped onto the tongue , contained in gel capsule s, or applied to the skin directly. However, it is also available in pill forms or as an inhalant.

What Are the Benefits of CBD for Seniors with Dementia?

CBD is commonly used to help with anxiety, insomnia, poor sleep, and even pain relief. B ecause CBD has been shown to help reduce anxiety and agitation, it is believed that it can help reduce these symptoms in seniors with dementia.

Because of how dementia affects the brain, a senior may become agitated or anxious in everyday situations. Sometimes this agitation can even turn vio lent. But remember that these behavior changes are caused by the disease and are not your loved one’s fault. CBD may be able to help alleviate these symptoms .

Additionally, Dementia Care Central indicates that CBD may also help:

  • Reduce inflammation
  • Reduce oxygen buildup
  • Stimulate the brain & reduce the decline of memory and other brain functions

Let’s dive deeper into how CBD could help in each of these areas.

Inflammation

Inflammation is the body’s natural response to injury. You might be used to seeing inflammation around a cut or wound. However, neuroinflammation is also associated with various forms of dementia. For example, Alzheimer’s disease causes clumps of proteins to build up in the brain. This can make it harder for the brain to function over time. As a result, the body may respond with inflammation in the area, which could make it even harder for the brain to make connections. However, CBD may help reduce that inflammation and help with dementia.

Oxygen Buildup

Oxygen buildup ties in with inflammation in the brain. As brain tissue expands, oxygen is released. So, the more inflammation, the more oxygen that builds up. As more oxygen is released into the brain, the brain loses functionality. This can result in memory loss or other brain deterioration. Oxygen is also released when the body is stressed, which happens often for seniors with dementia. CBD may help reduce stress and reduce the negative effects of oxygen on the brain.

Memory & Brain Function

As dementia progresses, brain tissue actually dies and function is lost for good. This process can take the time or it can happen very rapidly. In some trials, CBD showed promising results to help stop or even reverse the loss of brain function and memory loss in dementia patients. Additionally, CBD may help stimulate the brain to help keep connections within the brain and help seniors potentially delay the effects of dementia.

While this information gives us much hope in the fight against dementia, know that only small clinical trials have been conducted to determine the effects of CBD on dementia, making it difficult to come to a scientific conclusion. However, scientists are continuing to conduct rese arch to help further our ability to help those with dementia.

Are There Any Risks Associated with CBD?

The World Health Organization (WHO ) has stated that “no public health problems. have been associated with the use of pure CBD.” Additionally, it does not exhibit addictive properties and has not been shown to cause any health risks.

However, this applies to pure CBD. There are some retailers who produce CBD products with other ingredients or strains of CBD that have been tainted with other substances. Some companies also misrepresent their products and place different packaging labels on the products. This could pose a risk for your loved one, so i t’s important for you to obtain any CBD products through a company that has been approved by a third party , meaning the products have been tested independently for quality.

If you or your loved one is interested in using CBD to manage symptoms, make sure you talk to a doctor first to evaluate the risks and discuss the best options.

There is still much we do not know when it comes to CBD and its effectiveness in treating the symptoms of dementia. However, we are hopeful that new research and medications will be developed that will end dementia for good!